(LOOTPRESS) – Novo Nordisk announced Monday that it is lowering the cost of its diabetes drug Ozempic for U.S. patients who pay out of pocket, offering the medication for $499 per month—less than half its current list price of nearly $1,350.

The discounted price applies to three dose sizes of the weekly injection and is available through Novo Nordisk’s official website, its patient assistance program, and the company’s new direct-to-consumer online pharmacy, which ships Ozempic directly to patients. Drug savings company GoodRx will also make the $499 price available at more than 70,000 pharmacies nationwide, including for Wegovy, Ozempic’s sister drug for weight loss.

The move comes as drugmakers face increasing political and public pressure to lower costs. In July, President Donald Trum

See Full Page